Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.61 USD | +2.71% | -0.66% | -25.23% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-25.23% | 3.05B | B | ||
-1.42% | 41.35B | B | ||
+42.15% | 40.38B | A | ||
+1.97% | 39.05B | B- | ||
-14.19% | 26.67B | C | ||
+1.82% | 24.07B | B- | ||
-24.55% | 18.36B | B | ||
-4.07% | 11.68B | C+ | ||
+21.36% | 11.6B | C+ | ||
+8.20% | 11.15B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- FOLD Stock
- Ratings Amicus Therapeutics, Inc.